Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

iwAL 2019 Session II

Optimization of Standard Treatment in AML

In session II of iwAL 2019, Adriano Venditti, MD,
Bob Löwenberg, MD, PhD and Richard Larson, MD, present risk-adapted therapies for primary AML based on genetics and MRD, frontline treatments in AML and treatment and outcomes of AML in older patients.

Presentations
Treatment and outcomes of AML in older adults
Richard Larson
The University of Chicago Medicine, Chicago, IL
4 May, 2019
Risk adapted therapies for primary AML based on genetics and MRD
Adriano Venditti
University of Rome Tor Vergata, Rome, Italy
4 May, 2019
Frontline treatments in AML
Bob Löwenberg
Erasmus University Medical Center, Rotterdam, The Netherlands
4 May, 2019